Abstract:
|
Breast implant-associated anaplastic large-cell lymphoma (ALCL) is a rare type of lymphoma and the first case was described in 1997. Since this lymphoma is recently recognized, the diagnosis is frequently missed as a lymphoma or confounded as a systemic ALCL, thus patients receive a variety of therapies that often lead to repeated disease relapse or progression of disease to a more aggressive lymphoma. Our study followed up 87 cases longitudinally and collected both the recurrent events and the survival data. When analyzing the recurrent event data, the assumption of a non-informative censoring is often required. However, this non-informative censoring assumption is violated in our study since the survival time is believed to be correlated with the repeated disease relapse. Considering such an informative censoring, we use a joint frailty model to estimate the effects of clinical factors and treatments on the recurrent disease relapse and survival simultaneously.
|
ASA Meetings Department
732 North Washington Street, Alexandria, VA 22314
(703) 684-1221 • meetings@amstat.org
Copyright © American Statistical Association.